Cargando…

Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies

PURPOSE: Pooled evaluation of the key efficacy and safety profile of eslicarbazepine acetate (ESL) added‐on to stable antiepileptic therapy in adults with focal‐onset seizures. METHODS: Data from 1703 patients enrolled in four phase III double‐blind, randomized, placebo‐controlled studies were poole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elger, Christian, Koepp, Mathias, Trinka, Eugen, Villanueva, Vicente, Chaves, João, Ben‐Menachen, Elinor, Kowacs, Pedro A., Gil‐Nagel, António, Moreira, Joana, Gama, Helena, Rocha, José‐Francisco, Soares‐da‐Silva, Patrício
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813188/ https://www.ncbi.nlm.nih.gov/pubmed/29030894 http://dx.doi.org/10.1111/cns.12765

Ejemplares similares

Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
por: Trinka, Eugen, et al.
Publicado: (2020)

Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience
por: Gama, Helena, et al.
Publicado: (2017)

Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: post hoc analysis of a phase III trial and open-label extension study
por: Trinka, Eugen, et al.
Publicado: (2023)

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
por: Costa, Raquel, et al.
Publicado: (2018)

Safety of Eslicarbazepine Acetate in Elderly Versus Non-Elderly Patients with Focal Seizures: From Pooled Data of Clinical Studies to 8 Years of Post-Marketing Experience
por: Magalhães, Luís M., et al.
Publicado: (2021)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
por: Soares-da-Silva, Patrício, et al.
Publicado: (2015)

Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate
por: Koepp, Matthias J., et al.
Publicado: (2023)

Eslicarbazepine Acetate Modulates EEG Activity and Connectivity in Focal Epilepsy
por: Pellegrino, Giovanni, et al.
Publicado: (2018)

Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies
por: Shorvon, S. D., et al.
Publicado: (2017)

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
por: Altalib, Hamada, et al.
Publicado: (2022)

Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy
por: Saxena, S., et al.
Publicado: (2021)

Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
por: Mintz, Mark, et al.
Publicado: (2019)

Eslicarbazepine acetate in post‐stroke epilepsy: Clinical practice evidence from Euro‐Esli
por: Sales, Francisco, et al.
Publicado: (2020)

Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
por: Lawthom, Charlotte, et al.
Publicado: (2018)

Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies
por: Sperling, Michael R., et al.
Publicado: (2016)

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study
por: Chaves, J., et al.
Publicado: (2017)

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
por: Sperling, Michael R, et al.
Publicado: (2015)

Adjunctive Treatment With Eslicarbazepine Acetate for Adults and Children With Focal-Onset Epilepsy: A Meta-Analysis
por: Fei, Yanqing, et al.
Publicado: (2022)

Serum sodium levels and related treatment‐emergent adverse events during eslicarbazepine acetate use in adults with epilepsy
por: Wechsler, Robert T., et al.
Publicado: (2019)

Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses
por: Mehta, Darshan, et al.
Publicado: (2020)

Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
por: Mehta, Darshan, et al.
Publicado: (2021)

Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’
por: Öztiryaki, Ahmet H., et al.
Publicado: (2010)

Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus
por: Sierra-Paredes, Germán, et al.
Publicado: (2014)

Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures
por: Villanueva, Vicente, et al.
Publicado: (2017)

Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy
por: Tambucci, Renato, et al.
Publicado: (2016)

A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal-Onset Epilepsy
por: Hirsch, Martin, et al.
Publicado: (2023)

Healthcare Resource Utilization Pre- and Post-Initiation of Eslicarbazepine Acetate Among Pediatric Patients with Focal Seizure: Evidence from Routine Clinical Practice
por: Mehta, Darshan, et al.
Publicado: (2020)

Bioequivalence of Eslicarbazepine Acetate from Two Different Sources of its Active Product Ingredient in Healthy Subjects
por: Falcão, Amílcar, et al.
Publicado: (2013)

Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials
por: Carreño, Mar, et al.
Publicado: (2017)

A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy
por: Singh, Rajinder P., et al.
Publicado: (2011)

Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate
por: Gidal, B. E., et al.
Publicado: (2018)

Transition from oxcarbazepine to eslicarbazepine acetate: A single center study
por: Mäkinen, Jussi, et al.
Publicado: (2017)

Healthcare Resource Utilization Among Patients with Focal Seizures Treated with Eslicarbazepine Acetate in the US Long-Term Care Setting: A Retrospective Claims Database Analysis
por: Mehta, Darshan, et al.
Publicado: (2021)

Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
por: Galiana, Graciana L., et al.
Publicado: (2017)

Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures
por: Sunkaraneni, Soujanya, et al.
Publicado: (2018)

Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Na(v)1.5 Channels
por: Leslie, Theresa K., et al.
Publicado: (2020)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study
por: Winter, Yaroslav, et al.
Publicado: (2022)

Development of a stress induced validated UPLC-PDA method for the analysis of Eslicarbazepine acetate
por: Iram, Farah, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4lmc5ie5m0sj27p97ifu7eu21a